To access prescribing information for Janssen products not listed click prescribing information
PRESCRIBING INFORMATION
Alphabetical by Janssen brand name
DARZALEX® 20 mg/ml concentrate for solution for infusion
ACTIVE INGREDIENT(s): daratumumab
Click to view DARZALEX® prescribing information
EDURANT® 25 mg film-coated tablet
ACTIVE INGREDIENT(s): rilpivirine
Click to view EDURANT® prescribing information
IMBRUVICA® 140mg hard capsules
ACTIVE INGREDIENT(s): ibrutinib
Click to view IMBRUVICA® prescribing information
INTELENCE® 25 mg, 100 mg & 200 mg tablets
ACTIVE INGREDIENT(s): etravirine
Click to view INTELENCE® prescribing information
INVEGA® 3 mg, 6 mg, 9 mg and 12 mg prolonged-release tablets
ACTIVE INGREDIENT(s): paliperidone
Click to view INVEGA® prescribing information
PREZISTA® 100mg/ml oral suspension and 75mg, 150mg, 400mg, 600mg and 800mg film-coated tablets
ACTIVE INGREDIENT(s): darunavir
Click to view PREZISTA® prescribing information
PREZISTA 100 mg/ml oral suspension
PREZISTA 75 mg film-coated tablets
PREZISTA 150 mg film-coated tablets
PREZISTA 400 mg film-coated tablets
PREZISTA 600 mg film-coated tablets
PREZISTA 800 mg film coated tablets
REZOLSTA® 800 mg/150 mg film-coated tablets
ACTIVE INGREDIENT(s): darunavir and cobicistat
Click to view REZOLSTA® prescribing information
RISPERDAL® CONSTA® 25mg, 37.5mg and 50mg injection
ACTIVE INGREDIENT(s): risperidone
Click to view RISPERDAL®CONSTA® prescribing information
RISPERDAL® CONSTA® 25 mg injection
RISPERDAL® CONSTA® 37.5 mg injection
RISPERDAL® CONSTA® 50 mg injection
RISPERDAL® film-coated tablets and oral solution
ACTIVE INGREDIENT(s): risperidone
Click to view RISPERDAL® film-coated tablets and oral solution prescribing information
RISPERDAL 0.5 mg film-coated tablets
RISPERDAL 1 mg film-coated tablets
RISPERDAL 2 mg film-coated tablets
RISPERDAL 3 mg film-coated tablets
RISPERDAL 4 mg film-coated tablets
RISPERDAL 6 mg film-coated tablets
STELARA® concentrate for solution for infusion, solution for injection (vial) and solution for injection in pre-filled syringe
ACTIVE INGREDIENT(s): ustekinumab
Click to view STELARA® prescribing information
STELARA 130 mg concentrate for solution for infusion
TREVICTA® 175 mg, 263 mg, 350 mg & 525 mg prolonged release suspension for injection
ACTIVE INGREDIENT(s): paliperidone palmitate
Click to view TREVICTA® prescribing information
VELCADE® 3.5 mg powder for solution for injection
ACTIVE INGREDIENT(s): bortezomib
Click to view VELCADE® prescribing information
XEPLION® 25 mg, 50 mg, 75 mg, 100 mg & 150 mg prolonged-release suspension for injection
ACTIVE INGREDIENT(s): paliperidone palmitate
Click to view XEPLION® prescribing information
ZYTIGA® 500 mg Tablets
ACTIVE INGREDIENT(s): abiraterone acetate
Click to view ZYTIGA® prescribing information
ZYTIGA 500 mg film-coated tablets
Adverse events should be reported. This medicinal product is subject to additional monitoring and it is therefore important to report any suspected adverse reactions related to this medicinal product. Reporting forms and information can be found at www.HPRA.IE. Adverse events should also be reported to Janssen-Cilag Limited on 001494 567447 or at [email protected].
Content Date of Preparation: August 2017
Item code: PHIR/NPR/0817/0001h